The Sympathetic Nervous System in Heart Failure. Physiology, Pathophysiology, and Clinical Implications

Journal of the American College of Cardiology

Volumn 54, Issue 19, 2009, Pages 1747-1762

  Triposkiadis, Filippos ^a   Karayannis, George ^a   Giamouzis, Grigorios ^a,c   Skoularigis, John ^a   Louridas, George ^b   Butler, Javed ^c  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c EMORY UNIVERSITY   (United States)

Author keywords

adrenergic receptor; beta blockers; heart failure; sympathetic nervous system; sympatholytics; sympathomimetic inotropes

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENERGIC RECEPTOR; ALPRENOLOL; ATENOLOL; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CATECHOLAMINE; CELIPROLOL; CLONIDINE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOXAZOSIN; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; LABETALOL; METOPROLOL; MILRINONE; MOXONIDINE; NADOLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PLACEBO; PRAZOSIN; PROPRANOLOL; TIMOLOL; UNINDEXED DRUG;

ADRENERGIC SYSTEM; AIRWAY PRESSURE; CARDIOTOXICITY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HUMAN; MODULATION; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; DIGOXIN; EXERCISE TOLERANCE; HEART FAILURE; HEMODYNAMICS; HUMANS; PARASYMPATHETIC NERVOUS SYSTEM; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-2; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; SYMPATHOMIMETICS;

EID: 70350513886     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.05.015     Document Type: Review

References (167)

1. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
2. Zipes D.P. Heart-brain interactions in cardiac arrhythmias: role of the autonomic nervous system. Cleve Clin J Med 75 Suppl 2 (2008) S94-S96
3. Pierpont G.L., DeMaster E.G., Reynolds S., Pederson J., and Cohn J.N. Ventricular myocardial catecholamines in primates. J Lab Clin Med 106 (1985) 205-210
4. Armour J.A. Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol 287 (2004) R262-R271
5. Malliani A., Pagani M., Pizzinelli P., Furlan R., and Guzzetti S. Cardiovascular reflexes mediated by sympathetic afferent fibers. J Auton Nerv Syst 7 (1983) 295-301
6. Van Stee E.W. Autonomic innervation of the heart. Environ Health Perspect 26 (1978) 151-158
7. Quigg R.J., Rocco M.B., Gauthier D.F., Creager M.A., Hartley L.H., and Colucci W.S. Mechanism of the attenuated peak heart rate response to exercise after orthotopic cardiac transplantation. J Am Coll Cardiol 14 (1989) 338-344
8. Leineweber K., Wangemann T., Giessler C., et al. Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J Am Coll Cardiol 40 (2002) 1459
9. Bylund D., Bond R., Clarke D., et al. Adrenoceptors. The IUPHAR Compendium of Receptor Characterization and Classification (1998), IUPHAR, London 58-74
10. Bylund D.B., Eikenberg D.C., Hieble J.P., et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46 (1994) 121-136
11. Skeberdis V.A., Gendviliene V., Zablockaite D., et al. Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest 118 (2008) 3219-3227
12. Gauthier C., Leblais V., Kobzik L., et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102 (1998) 1377-1384
13. Rozec B., Erfanian M., Laurent K., Trochu J.N., and Gauthier C. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 53 (2009) 1532-1538
14. Lohse M.J., Engelhardt S., and Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 93 (2003) 896-906
15. Feldman D.S., Carnes C.A., Abraham W.T., and Bristow M.R. Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2 (2005) 475-483
16. Zhao X.L., Gutierrez L.M., Chang C.F., and Hosey M.M. The alpha 1-subunit of skeletal muscle L-type Ca channels is the key target for regulation by A-kinase and protein phosphatase-1C. Biochem Biophys Res Commun 198 (1994) 166-173
17. Ludwig A., Zong X., Jeglitsch M., Hofmann F., and Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature 393 (1998) 587-591
18. Sulakhe P.V., and Vo X.T. Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Mol Cell Biochem 149 (1995) 103-126
19. Despa S., Bossuyt J., Han F., et al. Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump function in cardiac myocytes. Circ Res 97 (2005) 252-259
20. Woodcock E.A., Du X.J., Reichelt M.E., and Graham R.M. Cardiac alpha 1-adrenergic drive in pathological remodelling. Cardiovasc Res 77 (2008) 452-462
21. Shannon R., and Chaudhry M. Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J 152 (2006) 842-850
22. Hein L. [The alpha 2-adrenergic receptors: molecular structure and in vivo function]. Z Kardiol 90 (2001) 607-612
23. Esler M., Jennings G., Lambert G., Meredith I., Horne M., and Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70 (1990) 963-985
24. Lahiri M.K., Kannankeril P.J., and Goldberger J.J. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol 51 (2008) 1725-1733
25. Kingwell B.A., Thompson J.M., Kaye D.M., McPherson G.A., Jennings G.L., and Esler M.D. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 90 (1994) 234-240
26. Esler M.D., Jennings G.L., Johns J., Burke F., Little P.J., and Leonard P. Estimation of "total" renal, cardiac and splanchnic sympathetic nervous tone in essential hypertension from measurements of noradrenaline release. J Hypertens Suppl 2 (1984) S123-S125
27. Vallbo A.B., Hagbarth K.E., and Wallin B.G. Microneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. J Appl Physiol 96 (2004) 1262-1269
28. Wieland D.M., Brown L.E., Rogers W.L., et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22 (1981) 22-31
29. Schwaiger M., Kalff V., Rosenspire K., et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 82 (1990) 457-464
30. Link J.M., and Caldwell J.H. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med 5 Suppl 2 (2008) S79-S86
31. Sisson J.C., Shapiro B., Meyers L., et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28 (1987) 1625-1636
32. Verberne H.J., Brewster L.M., Somsen G.A., and van Eck-Smit B.L. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 29 (2008) 1147-1159
33. Tamaki S., Yamada T., Okuyama Y., et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 53 (2009) 426-435
34. Jacobson A.F., Lombard J., Banerjee G., and Camici P.G. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 16 (2009) 113-121
35. Dzau V.J., Colucci W.S., Hollenberg N.K., and Williams G.H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63 (1981) 645-651
36. Pepper G.S., and Lee R.W. Sympathetic activation in heart failure and its treatment with beta-blockade. Arch Intern Med 159 (1999) 225-234
37. Morris M.J., Cox H.S., Lambert G.W., et al. Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 29 (1997) 137-143
38. Hogg K., and McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 47 (2005) 357-366
39. Grassi G., Seravalle G., Quarti-Trevano F., et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 53 (2009) 205-209
40. Regitz V., Leuchs B., Bossaller C., Sehested J., Rappolder M., and Fleck E. Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur Heart J 12 Suppl D (1991) 171-174
41. Backs J., Haunstetter A., Gerber S.H., et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a post-transcriptional downregulation. J Mol Cell Cardiol 33 (2001) 461-472
42. Lockhart S.T., Turrigiano G.G., and Birren S.J. Nerve growth factor modulates synaptic transmission between sympathetic neurons and cardiac myocytes. J Neurosci 17 (1997) 9573-9582
43. Watson A.M., Hood S.G., and May C.N. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 33 (2006) 1269-1274
44. Karayannis G., Kitsios G., Kotidis H., and Triposkiadis F. Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. Heart Fail Rev 13 (2008) 91-98
45. Leenen F.H. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circ Res 101 (2007) 221-223
46. Wang H., Huang B.S., Ganten D., and Leenen F.H. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ Res 94 (2004) 843-849
47. Lal A., Veinot J.P., and Leenen F.H. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 64 (2004) 437-447
48. Li Y.F., Wang W., Mayhan W.G., and Patel K.P. Angiotensin-mediated increase in renal sympathetic nerve discharge within the PVN: role of nitric oxide. Am J Physiol Regul Integr Comp Physiol 290 (2006) R1035-R1043
49. Garrido A.M., and Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 302 (2009) 148-158
50. Piacentino III V., Weber C.R., Chen X., et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 92 (2003) 651-658
51. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med 336 (1997) 1131-1141
52. Dodge-Kafka K.L., Soughayer J., Pare G.C., et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437 (2005) 574-578
53. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
54. Engelhardt S., Bohm M., Erdmann E., and Lohse M.J. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 27 (1996) 146-154
55. Perrino C., Naga Prasad S.V., Patel M., Wolf M.J., and Rockman H.A. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 45 (2005) 1862-1870
56. Noma T., Lemaire A., Naga Prasad S.V., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117 (2007) 2445-2458
57. Eschenhagen T. Beta-adrenergic signaling in heart failure-adapt or die. Nat Med 14 (2008) 485-487
58. Bohm M., Ettelbruck S., Flesch M., et al. Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res 40 (1998) 146-155
59. Liggett S.B., Tepe N.M., Lorenz J.N., et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101 (2000) 1707-1714
60. DeGeorge Jr. B.R., Gao E., Boucher M., et al. Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 117 (2008) 1378-1387
61. Moniotte S., Kobzik L., Feron O., Trochu J.N., Gauthier C., and Balligand J.L. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103 (2001) 1649-1655
62. Morimoto A., Hasegawa H., Cheng H.J., Little W.C., and Cheng C.P. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286 (2004) H2425-H2433
63. Knowlton K.U., Michel M.C., Itani M., et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 268 (1993) 15374-15380
64. Du X.J., Gao X.M., Kiriazis H., et al. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc Res 71 (2006) 735-743
65. Huang Y., Wright C.D., Merkwan C.L., et al. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 115 (2007) 763-772
66. Hein L., Altman J.D., and Kobilka B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 (1999) 181-184
67. Todd G.L., Baroldi G., Pieper G.M., Clayton F.C., and Eliot R.S. Experimental catecholamine-induced myocardial necrosis. II. Temporal development of isoproterenol-induced contraction band lesions correlated with ECG, hemodynamic and biochemical changes. J Mol Cell Cardiol 17 (1985) 647-656
68. Mann D.L., Kent R.L., Parsons B., and Cooper G.T. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85 (1992) 790-804
69. Brouri F., Hanoun N., Mediani O., et al. Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol 485 (2004) 227-234
70. Osadchii O.E., Norton G.R., McKechnie R., Deftereos D., and Woodiwiss A.J. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation. Am J Physiol Heart Circ Physiol 292 (2007) H1898-H1905
71. Communal C., Singh K., Pimentel D.R., and Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98 (1998) 1329-1334
72. Fu Y.C., Chi C.S., Yin S.C., Hwang B., Chiu Y.T., and Hsu S.L. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc Res 62 (2004) 558-567
73. Neri M., Cerretani D., Fiaschi A.I., et al. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J Cell Mol Med 11 (2007) 156-170
74. Wittstein I.S., Thiemann D.R., Lima J.A., et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352 (2005) 539-548
75. Lyon A.R., Rees P.S., Prasad S., Poole-Wilson P.A., and Harding S.E. Stress (Takotsubo) cardiomyopathy-a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 5 (2008) 22-29
76. Mori H., Ishikawa S., Kojima S., et al. Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli. Cardiovasc Res 27 (1993) 192-198
77. Sandilands A.J., O'Shaughnessy K.M., and Brown M.J. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol 138 (2003) 386-392
78. Levin M.C., Marullo S., Muntaner O., Andersson B., and Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277 (2002) 30429-30435
79. de Groote P., Helbecque N., Lamblin N., et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15 (2005) 137-142
80. Green S.A., Cole G., Jacinto M., Innis M., and Liggett S.B. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
81. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., and Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347 (2002) 1135-1142
82. Biolo A., Clausell N., Santos K.G., et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 102 (2008) 726-732
83. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
84. Borjesson M., Magnusson Y., Hjalmarson A., and Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21 (2000) 1853-1858
85. Terra S.G., Hamilton K.K., Pauly D.F., et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 15 (2005) 227-234
86. Mialet-Perez J., Rathz D.A., Petrashevskaya N.N., et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9 (2003) 1300-1305
87. Chen L., Meyers D., Javorsky G., et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 17 (2007) 941-949
88. Sehnert A.J., Daniels S.E., Elashoff M., et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52 (2008) 644-651
89. White H.L., de Boer R.A., Maqbool A., et al., MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5 (2003) 463-468
90. Magnusson Y., Levin M.C., Eggertsen R., et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78 (2005) 221-231
91. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
92. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
93. O'Connor C., Anand I., Fiuzat M., et al. Additive Effects of [beta]1 389 Arg/Gly [alpha]2c 322-325 Wt/Del genotype combinations on adjudicated hospitalizations and death in the Beta-Blocker Evaluation of Survival Trial (BEST). (abstr). J Card Fail 14 (2008) S69
94. Chemello D., Rohde L.E., Pimentel M., et al. Role of genetic polymorphisms to predict appropriate therapies in patients with implantable cardioverter defibrillators. (abstr). J Card Fail 14 (2008) S62
95. Lopez-Sendon J., Swedberg K., McMurray J., et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25 (2004) 1341-1362
96. Triposkiadis F., Giamouzis G., Kelepeshis G., Sitafidis G., Skoularigis J., and Demopoulos V. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int J Clin Pharmacol Ther 45 (2007) 71-77
97. Kaumann A.J., and Molenaar P. The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 118 (2008) 303-336
98. Sistonen J., Sajantila A., Lao O., Corander J., Barbujani G., and Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17 (2007) 93-101
99. Ingelman-Sundberg M., Sim S.C., Gomez A., and Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116 (2007) 496-526
100. Wuttke H., Rau T., Heide R., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72 (2002) 429-437
101. Fujimaki M. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved. Drug Metab Dispos 22 (1994) 700-708
102. Horikiri Y., Suzuki T., and Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci 87 (1998) 289-294
103. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
104. Waagstein F., Bristow M.R., Swedberg K., et al., Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342 (1993) 1441-1446
105. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
106. Packer M., Bristow M.R., Cohn J.N., et al., U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
107. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349 (1997) 375-380
108. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
109. Packer M., Fowler M.B., Roecker E.B., et al., Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
110. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al., Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
111. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90 (1994) 1765-1773
112. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
113. Willenheimer R., van Veldhuisen D.J., Silke B., et al., CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 (2005) 2426-2435
114. Flather M.D., Shibata M.C., Coats A.J., et al., Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
115. Adamson P.B., and Gilbert E.M. Reducing the risk of sudden death in heart failure with beta-blockers. J Card Fail 12 (2006) 734-746
116. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
117. Colucci W.S., Williams G.H., and Braunwald E. Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Ann Intern Med 93 (1980) 452-453
118. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 (2000) 1967-1975
119. Starke K., Gothert M., and Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69 (1989) 864-989
120. Giles T.D., Thomas M.G., Quiroz A., Rice J.C., Plauche W., and Sander G.E. Acute and short-term effects of clonidine in heart failure. Angiology 38 (1987) 537-548
121. Ernsberger P., Meeley M.P., Mann J.J., and Reis D.J. Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134 (1987) 1-13
122. Ernsberger P., Meeley M.P., and Reis D.J. An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res 441 (1988) 309-318
123. Lang C.C., Rayos G.H., Chomsky D.B., Wood A.J., and Wilson J.R. Effect of sympathoinhibition on exercise performance in patients with heart failure. Circulation 96 (1997) 238-245
124. Cohn J.N., Pfeffer M.A., Rouleau J., et al., MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-667
125. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 107 (2003) 1100-1102
126. Sumners C., and Raizada M.K. Angiotensin II stimulates norepinephrine uptake in hypothalamus-brain stem neuronal cultures. Am J Physiol 250 (1986) C236-C244
127. Weber M.A., and Purdy R.E. Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 30 (1982) 2009-2017
128. Benedict C.R., Francis G.S., Shelton B., et al., SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 75 (1995) 1151-1157
129. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
130. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
131. Petersen J.W., and Felker G.M. Inotropes in the management of acute heart failure. Crit Care Med 36 (2008) S106-S111
132. Grose R., Strain J., Greenberg M., and LeJemtel T.H. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 7 (1986) 1107-1113
133. Triposkiadis F., Dalampiras P., Kelepeshis G., Skoularigis J., and Sitafidis G. Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol. Int J Clin Pharmacol Ther 46 (2008) 136-139
134. Massie B.M., Berk M.R., Brozena S.C., et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor?. Results of the Flosequinan-ACE inhibitor Trial (FACET). Circulation 88 (1993) 492-501
135. Packer M., Medina N., and Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70 (1984) 1038-1047
136. Packer M., Carver J.R., Rodeheffer R.J., et al., PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
137. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
138. Abraham W.T., Adams K.F., Fonarow G.C., et al., ADHERE Scientific Advisory Committee and Investigators, ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 (2005) 57-64
139. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 1873-1884
140. Soppa G.K., Lee J., Stagg M.A., et al. Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 77 (2008) 695-706
141. Kamalakkannan G., Petrilli C.M., George I., et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant 27 (2008) 457-461
142. Mancini D.M., Walter G., Reichek N., et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 85 (1992) 1364-1373
143. Khan M.H., and Sinoway L.I. Muscle reflex control of sympathetic nerve activity in heart failure: the role of exercise conditioning. Heart Fail Rev 5 (2000) 87-100
144. Negrao C.E., and Middlekauff H.R. Adaptations in autonomic function during exercise training in heart failure. Heart Fail Rev 13 (2008) 51-60
145. Nechwatal R.M., Duck C., and Gruber G. [Physical training as interval or continuous training in chronic heart failure for improving functional capacity, hemodynamics and quality of life-a controlled study]. Z Kardiol 91 (2002) 328-337
146. Fraga R., Franco F.G., Roveda F., et al. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. Eur J Heart Fail 9 (2007) 630-636
147. O'Connor C.M., Whellan D.J., Lee K.L., et al., HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009) 1439-1450
148. Adams V., Doring C., and Schuler G. Impact of physical exercise on alterations in the skeletal muscle in patients with chronic heart failure. Front Biosci 13 (2008) 302-311
149. Gao L., Wang W., Liu D., and Zucker I.H. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. Circulation 115 (2007) 3095-3102
150. Olshansky B., Sabbah H.N., Hauptman P.J., and Colucci W.S. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118 (2008) 863-871
151. Azevedo E.R., and Parker J.D. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 100 (1999) 274-279
152. Kubo T., Parker J.D., Azevedo E.R., et al. Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover. Eur J Heart Fail 7 (2005) 878-881
153. Xu X.L., Zang W.J., Lu J., Kang X.Q., Li M., and Yu X.J. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton Neurosci 130 (2006) 6-16
154. Goldsmith R.L., Bigger J.T., Bloomfield D.M., et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 80 (1997) 1101-1104
155. Bibevski S., and Dunlap M.E. Prevention of diminished parasympathetic control of the heart in experimental heart failure. Am J Physiol Heart Circ Physiol 287 (2004) H1780-H1785
156. Sabbah H.N., Rastogi S., Mishra S., et al. Long-term therapy with neuroselective electric vagus nerve stimulation improves LV function and attenuates global LV remodelling in dogs with chronic heart failure. Eur J Heart Fail (Suppl) 4 (2005) 166
157. Pervaiz M.H., Dickinson M.G., and Yamani M. Is digoxin a drug of the past?. Cleve Clin J Med 73 (2006) 821-834
158. Thames M.D., Miller B.D., and Abboud F.M. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol 243 (1982) H815-H818
159. Krum H., Bigger Jr. J.T., Goldsmith R.L., and Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 25 (1995) 289-294
160. Ferguson D.W., Berg W.J., Sanders J.S., Roach P.J., Kempf J.S., and Kienzle M.G. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 80 (1989) 65-77
161. Gheorghiade M., van Veldhuisen D.J., and Colucci W.S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 113 (2006) 2556-2564
162. Bradley T.D., and Floras J.S. Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation 107 (2003) 1671-1678
163. Bradley T.D., and Floras J.S. Sleep apnea and heart failure: part II: central sleep apnea. Circulation 107 (2003) 1822-1826
164. Ruttanaumpawan P., Gilman M.P., Usui K., Floras J.S., and Bradley T.D. Sustained effect of continuous positive airway pressure on baroreflex sensitivity in congestive heart failure patients with obstructive sleep apnea. J Hypertens 26 (2008) 1163-1168
165. Khayat R.N., Abraham W.T., Patt B., Roy M., Hua K., and Jarjoura D. Cardiac effects of continuous and bilevel positive airway pressure for patients with heart failure and obstructive sleep apnea: a pilot study. Chest 134 (2008) 1162-1168
166. Bradley T.D., Logan A.G., Kimoff R.J., et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 (2005) 2025-2033
167. Arzt M., Floras J.S., Logan A.G., et al., CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 115 (2007) 3173-3180